口服氯氮平精神分裂症患者的白细胞水平监测

White blood cells level monitoring in schizophrenia patients with oral administration of clozapine

目的监测口服氯氮平精神分裂症患者白细胞(WBC)数量的变化,根据白细胞数量的消长变化情况指导临床用药。方法对30例长期服用氯氮平的精神病分裂症患者用药前后,各不同阶段进行血常规检测,对比白细胞变化情况。结果用药前精神分裂症患者的白细胞水平均在正常范围。但随着用药时间的推移,白细胞数量逐级下降,与治疗前的(8.42±1.30)×109/L比较差异均有统计学意义(P<0.05)。结论氯氮平不仅能改善精神分裂症的症状,还能干扰患者机体的正常生理调节,造成免疫力下降,出现并发症。通过监测白细胞的变化,对于临床上尽早避免患者并发症出现具有一定的治疗意义。

Objective To monitor white blood cells（WBC） count changes in schizophrenia patients with oral administration of clozapine, and to guide clinical medication in accordance with white blood cells count. Methods Blood routine examination was taken by 30 schizophrenia patients with long-term oral administration of clozapine before and after drug administration to compare white blood cells changes. Results Before medication, all patients had normal white blood cells level. Along with their medication progress, their white blood cells gradually decreased. Comparing with（8.42±1.30）×10^9/L before treatment, the difference had statistical significance（P〈0.05）. Conclusion Clozapine can not only improve schizophrenia symptoms, but also disturb normal physiological accommodation, lead to immunity decline and complications. White blood cells monitoring contains certain significance in treatment for early prevention of complications.